Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$abbv $104.97 ^ 0.77 (0.74%)
Volume: 4,418,751 @11/27/20 5:00:00 PM EST
JUST IN: $ABBV Like Dividends? I Bet You'll Love These 3 Stocks
Investment fads come and go, and growth stories eventually end. Income-producing stocks always fit into a portfolio, however, even if those dividends are being collected to purchase other sorts of positions. And, given the uncertainty that lies in our immediate future, a little more certain...
In case you are interested ABBV - Like Dividends? I Bet You'll Love These 3 Stocks
$abbv $99.0 ^ 1.4 (1.43%)
Volume: 6,877,285 @11/13/20 4:41:03 PM EST
$abbv $85.11 ^ 4.44 (5.50%)
Volume: 18,095,186 @10/30/20 7:58:30 PM EDT
Just In: $ABBV 5 No-Brainer Stocks to Buy if Donald Trump Wins in November
Talking heads get paid to speculate about what the market will do in different scenarios, but it is rare that anyone can truly know how a particular company, industry, or the overall market will fare based on a presidential election. That said, a reelection of a U.S. President offers mo...
Got this from ABBV - 5 No-Brainer Stocks to Buy if Donald Trump Wins in November
Just In: $ABBV AbbVie (ABBV) Q3 2020 Earnings Call Transcript
Image source: The Motley Fool. AbbVie (NYSE: ABBV) Q3 2020 Earnings Call Oct 30, 2020 , 9:00 a.m. ET Operator Continue reading For further details see: AbbVie (ABBV) Q3 2020 Earnings Call Transcript
In case you are interested ABBV - AbbVie (ABBV) Q3 2020 Earnings Call Transcript
News; $ABBV How AbbVie Beat Expectations in Q3
AbbVie (NYSE: ABBV) hasn't exactly given investors a lot to get excited about so far in 2020. As of Thursday's close, its shares were down by 9% year to date, lagging well behind the S&P 500 index 's performance. However, the big drugmaker's shareholders now have a reaso...
In case you are interested ABBV - How AbbVie Beat Expectations in Q3
News; $ABBV AbbVie Reports Third-Quarter 2020 Financial Results
AbbVie Reports Third-Quarter 2020 Financial Results - Reports Third-Quarter Diluted EPS of $1.29 on a GAAP Basis; Adjusted Diluted EPS of $2.83 - Delivers Third-Quarter Net Revenues of $12.902 Billion on a GAAP Basis, an Increase of 52.1 Percent on a Reported Basis; Adjusted...
Read the whole news ABBV - AbbVie Reports Third-Quarter 2020 Financial Results
Breaking News: $ABBV 2 No-Brainer Dividend Stocks Yielding More Than 4%
For dividend-seeking investors, looking at a stock's yield is important. High yields tend to be more attractive than low yields if all other things remain equal. But in real life, things are rarely equal, so before purchasing shares of a company because of its dividend, it's essential to lo...
Got this from ABBV - 2 No-Brainer Dividend Stocks Yielding More Than 4%
AbbVie (NYSE:ABBV) declares $1.30/share quarterly dividend, 10.2% increase from prior dividend of $1.18.
Forward yield 6.45%
Payable Feb. 16; for shareholders of record Jan. 15; ex-div Jan. 14.
ABBV 3Q20 results—2020 guidance raised slightly:
https://investors.abbvie.com/news-releases/news-release-details/abbvie-reports-third-quarter-2020-financial-results
New 2020 non-GAAP EPS guidance is $10.47-10.49 (from prior range of $10.35-10.45).
ABBV phase-3 trials in presbyopia hit primary endpoint:
https://finance.yahoo.com/news/allergan-abbvie-company-announces-positive-120000680.html
Detailed data to be presented at an unspecified medical conference.
AGN-190584, a once-daily eye drop, was inherited from Allergan.
ABBV is in a low risk buying range, IMO.
Healthy dividend. "Healthy" sector.
$abbv $83.01 v -1.24 (-1.47%)
Volume: 9,746,011 @10/21/20 7:58:03 PM EDT
The Race To Treat Spinal Cord Injury is On: AbbVie pharmaceuticals $ABBV and RespireRx Pharmaceuticals Inc. (RSPI) on Watch https://dailytrendingstocks.com/the-race-to-treat-spinal-cord-injury-is-on-abbvie-pharmaceuticals-abbv-and-respirerx-pharmaceuticals-inc-rspi-on-watch/?source=push_monkey
JUST IN: $ABBV Got $5,000? Here Are 2 Dividend Growth Stocks to Buy and Hold for Decades
If you are in a financial position to invest $5,000 in new stocks today, you will find no shortage of exciting options. If you would like to balance the potential for solid returns with long-term stability, dividend stocks might be the best place to start your search. Companies that have a ...
Find out more ABBV - Got $5,000? Here Are 2 Dividend Growth Stocks to Buy and Hold for Decades
$abbv $88.45 ^ 0.75 (0.86%)
Volume: 7,312,995 @10/12/20 5:52:38 PM EDT
$abbv $90.49 ^ 0.79 (0.88%)
Volume: 5,212,480 @09/14/20 7:49:58 PM EDT
$abbv $89.74 ^ 0.09 (0.10%)
Volume: 8,385,750 @09/11/20 7:58:55 PM EDT
ABBV, IMAB ink deal to commercialize IMAB’s anti-CD47 mAb globally (excluding Greater China):
https://finance.yahoo.com/news/abbvie-mab-enter-global-strategic-110000707.html
Good for ABBVIE delay for Gilead Sciences & (galapagos) rheumatoid arthritis (RA)
Mechelen, Belgium; 19 August 2020, 01.25 CET; regulated information – Galapagos (Euronext & Nasdaq: GLPG) announces today that Gilead Sciences, Inc. (Nasdaq: GILD) received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for filgotinib, an investigational treatment for moderately to severely active rheumatoid arthritis (RA). The FDA issues CRLs to indicate that the review cycle for an application is complete and that the application is not ready for approval in its present form. Gilead is the market authorization holder for filgotinib in the United States and is responsible for potential commercialization in the U.S.
The FDA has requested data from the MANTA and MANTA-RAy studies before completing its review of the NDA. The MANTA and MANTA-RAy studies are designed to assess whether filgotinib has an impact on sperm parameters. The FDA also has expressed concerns regarding the overall benefit/risk profile of the filgotinib 200 mg dose.
“We are disappointed in this outcome and will evaluate the points raised in the CRL for discussion with the FDA. We continue to believe in the benefit/risk profile of filgotinib in RA, which has been demonstrated in the FINCH Phase 3 clinical program,” said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences.
“This CRL issued by the FDA is very disappointing given the robust and comprehensive data package provided. Despite today’s news, we continue to believe filgotinib has the potential to provide an effective, new treatment option for patients with rheumatoid arthritis, where there remains a significant unmet need,” said Dr. Walid Abi-Saab, Chief Medical Officer, Galapagos.
The MANTA and MANTA-RAy studies are fully recruited, with topline results anticipated in the first half of 2021. Filgotinib is currently under review by regulatory authorities around the world. Filgotinib recently received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use, recommending marketing authorization for filgotinib in the EU for the treatment of adults with moderate to severe RA who have responded inadequately or are intolerant of one or more disease-modifying anti-rheumatic drugs.
$abbv $92.8 ^ 0.23 (0.25%)
Volume: 5,227,110 @08/07/20 7:59:47 PM EDT
$abbv $94.31 v -1.63 (-1.70%)
Volume: 7,865,116 @08/04/20 7:58:12 PM EDT
ABBV 2Q20 results/full-year-2020 guidance:
https://news.abbvie.com/news/press-releases/abbvie-reports-second-quarter-2020-financial-results.htm
New 2020 non-GAAP EPS guidance = $10.35-10.45, including $0.70 accretion from AGN acquisition.
Atogepant phase-3 succeeds in migraine prevention:
https://finance.yahoo.com/news/abbvie-announces-positive-phase-3-124500900.html
$abbv $100.83 ^ 0.91 (0.91%)
Volume: 6,896,147 @07/17/20 7:51:43 PM EDT
ABBV’s DARPin receives CRL in AMD due to still-high rate of intraocular inflammation:
https://www.prnewswire.com/news-releases/allergan-an-abbvie-company-and-molecular-partners-receive-complete-response-letter-from-fda-on-biologics-license-application-for-abicipar-pegol-301084188.html
FDA approves Voluma for chin enhancement:
https://finance.yahoo.com/news/fda-approves-juv-derm-voluma-121500053.html
$ABBV On breakout watch above $100
P/E ratio 17.15
Company profile
AbbVie , Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
This is the biggest theft in history for human pockets. Why do companies not rise dramatically when the market jumps 1700 points! But when the market goes down, all companies scramble with the Dow
ABBV forms collaboration to develop COVID-19 antibody for prophylaxis and treatment:
https://www.prnewswire.com/news-releases/abbvie-harbour-biomed-utrecht-university-and-erasmus-medical-center-announce-collaboration-to-develop-monoclonal-antibody-therapy-to-prevent-and-treat-covid-19-301071164.html
ABBV completes $65B AGN acquisition:
https://www.allergan.com/News/Details/2020/05/AbbVie%20Inc%20Completes%20Acquisition%20of%20Allergan%20plc
The deal, announced in Jun 2019 (#msg-149577810), entitles each AGN share to receive 0.886 shares of ABBV plus $120.30 in cash, a nominal value of $194.69/sh (3% higher than the nominal value of $188.24/sh nominal value at the time of the deal announcement).
1Q20 worldwide Botox sales=$812.2M, -6% YoY, -20% QoQ*:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=155520490
ABBV-AGN merger expected to close 5/8/20:
https://finance.yahoo.com/news/announcement-relating-outcome-court-sanction-105500126.html
Followers
|
80
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
768
|
Created
|
12/08/12
|
Type
|
Free
|
Moderators DewDiligence |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |